The FDA has given the green light to new COVID-19 vaccines from Pfizer and Moderna, but fewer than 25% of Americans are anticipated to get the shot.
Vaccines are set to begin shipping in the next few days. However, despite a COVID-19 resurgence in some regions, interest in receiving the latest vaccine or booster is at an all-time low.
The drop in demand has negatively impacted both Pfizer and Moderna. Earlier this year, Moderna reported a $1.2 billion loss due to a collapse in COVID-19 vaccine sales, a sharp contrast to the billions in profits it previously earned during the pandemic.
As reported by The New York Times:
The availability of boosters has not translated into actual vaccinations. By spring, only one in five adults had received last year’s updated Covid vaccine. Even older Americans, who are at far greater risk of being severely sickened, largely spurned the shots, with only 40 percent of people 75 and older taking last year’s vaccine.
The prospects for this year’s rollout remain dim. Older people were still dubious about the need for additional doses, doctors said. The Biden administration has been scrambling to find money to vaccinate uninsured Americans.
And public health